← Every company
Takeda Pharmaceutical Co Ltd Patents
What Takeda Pharmaceutical Co Ltd has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
TAK on carbonthat →Filings on file
52
Granted
3
Still pending
49
Filed under
2 names
52 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| METHODS FOR TREATMENT USING ANTI-ALPHA4BETA7 ANTIBODYA61K 39/395, A61K 39/39591, A61K 47/26, C07K 16/2839, A61P 37/00, A61P 37/02, A61P 1/00, A61P 29/00, A61P 1/04, A61K 9/0019, A61K 9/08, A61K 9/19, A61K 47/183, A61K 47/22, A61K2039/505, A61K2039/54, A61K2039/545, C07K2317/14, C07K2317/24, C07K2317/565, C07K2317/92, C07K2317/94Filed as Takeda Pharmaceutical Company Limited2026-06-17Irving H. Fox | pending |
| COMPOSITIONS FOR TREATING ULCERATIVE COLITISA61K 39/39591, C07K 16/2839, A61P 43/00, A61P 1/16, A61P 37/06, A61P 1/18, A61P 31/18, A61P 3/10, A61P 1/00, A61P 29/00, A61P 1/04, A61K 9/0019, A61K 9/08, A61K 47/12, A61K 47/14, A61K 47/183, A61K 47/22, A61K 47/26, A61K2039/505, A61K2039/54, A61K2039/545, C07K2317/24Filed as Takeda Pharmaceutical Company Limited2026-06-02Irving H. Fox | pending |
| ARTICLE OF MANUFACTURE FOR TREATING CROHNS DISEASEA61K 39/39591, C07K 16/2839, A61P 43/00, A61P 1/16, A61P 37/06, A61P 1/18, A61P 31/18, A61P 3/10, A61P 1/00, A61P 29/00, A61P 1/04, A61K 9/0019, A61K 9/08, A61K 47/12, A61K 47/14, A61K 47/183, A61K 47/22, A61K 47/26, A61K2039/505, A61K2039/54, A61K2039/545, C07K2317/24Filed as Takeda Pharmaceutical Company Limited2026-06-01Irving H. Fox | pending |
| BIOMARKERS AND USES THEREOF FOR TREATMENT OF CANCER WITH CD19-TARGETED ADOPTIVE CELL THERAPIESA61P 35/02, G01N 33/57585, A61K2239/48, A61K 40/15, A61K 40/4211, A61K 40/31, G01N 33/57505, G01N 33/56972, G01N2333/70503, G01N2800/52Filed as TAKEDA PHARMACEUTICAL COMPANY LIMITED2026-05-01Michel SADELAIN | pending |
| FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODYA61K 39/395, A61K 39/39591, A61K 47/26, C07K 16/2839, A61P 37/00, A61P 37/02, A61P 1/00, A61P 29/00, A61P 1/04, A61K 9/0019, A61K 9/08, A61K 9/19, A61K 47/183, A61K 47/22, A61K2039/505, A61K2039/54, A61K2039/545, C07K2317/14, C07K2317/24, C07K2317/565, C07K2317/92, C07K2317/94Filed as Takeda Pharmaceutical Company Limited2026-04-24Jason Brown | pending |
| ANTI-ALPHA4BETA7 ANTIBODY ARTICLES OF MANUFACTUREA61K 39/39591, C07K 16/2839, A61P 43/00, A61P 1/16, A61P 37/06, A61P 1/18, A61P 31/18, A61P 3/10, A61P 1/00, A61P 29/00, A61P 1/04, A61K 9/0019, A61K 9/08, A61K 47/12, A61K 47/14, A61K 47/183, A61K 47/22, A61K 47/26, A61K2039/505, A61K2039/54, A61K2039/545, C07K2317/24Filed as Takeda Pharmaceutical Company Limited2026-03-26Irving H. Fox | pending |
| METHOD OF TREATING CROHN'S DISEASEA61K 39/39591, C07K 16/2839, A61P 43/00, A61P 1/16, A61P 37/06, A61P 1/18, A61P 31/18, A61P 3/10, A61P 1/00, A61P 29/00, A61P 1/04, A61K 9/0019, A61K 9/08, A61K 47/12, A61K 47/14, A61K 47/183, A61K 47/22, A61K 47/26, A61K2039/505, A61K2039/54, A61K2039/545, C07K2317/24Filed as Takeda Pharmaceutical Company Limited2026-03-17Irving H. Fox | pending |
| METHOD OF TREATMENT WITH ANTI-ALPHA4BETA7 ANTIBODYA61K 39/39591, C07K 16/2839, A61P 43/00, A61P 1/16, A61P 37/06, A61P 1/18, A61P 31/18, A61P 3/10, A61P 1/00, A61P 29/00, A61P 1/04, A61K 9/0019, A61K 9/08, A61K 47/12, A61K 47/14, A61K 47/183, A61K 47/22, A61K 47/26, A61K2039/505, A61K2039/54, A61K2039/545, C07K2317/24Filed as Takeda Pharmaceutical Company Limited2026-03-17Irving H. Fox | pending |
| METHODS AND COMPOSITIONS FOR FREEZING AND THAWING MAMMALIAN CELLSA01N 1/125, A61K 40/15, A61P 35/00, A61K2239/25, A61K2239/13, A61K2239/21, A01N 1/142, A01N 1/126, A61K 40/31, A01N 1/162, C12N 5/0646, C12N2510/00Filed as Takeda Pharmaceutical Company Limited2026-02-18Shuxia Zhou | pending |
| MACROCYCLIC HETEROCYCLE COMPOUNDS AND USE THEREOFA61K 31/407, C07D 498/14, C07D 498/18, A61P 3/08, A61P 25/28, A61P 3/04, A61P 9/04, A61P 19/08, A61P 25/00, A61P 25/26, A61K 31/437, A61K 31/439, C07D 471/18, C07D 498/04Filed as TAKEDA PHARMACEUTICAL COMPANY LIMITED2026-01-20Mitsunori KONO | pending |
| GRID-FREE METHODS FOR MAKING GAMMA DELTA T CELLSC12N 5/0636, C12N 5/522, A61K 40/42, A61K 40/31, A61K 40/11, A61K 35/17, C12N 5/0087, C12N2500/32, C12N2500/90, C12N2501/23, C12N2501/2302, C12N2501/2304, C12N2501/2307, C12N2501/2312, C12N2501/2315, C12N2501/2321, C12N2501/998, C12N2506/09, C12N2506/23Filed as TAKEDA PHARMACEUTICAL COMPANY LIMITED2026-01-13Yamuna RAGHVANI | pending |
| NUCLEIC ACID-CONTAINING LIPID NANO-PARTICLE AND USE THEREOFA61K 9/5123, A61K 31/7105, A61K 39/0011, A61K 47/18, C12N 15/88, A61K 47/543, A61K 47/6929, A61P 37/04, A61P 35/00, A61K2239/48, A61K2239/31, A61K2239/38, A61K 40/4211, A61K 40/31, A61K 40/11, A61K 9/127, A61K 9/1272, A61K 31/711, A61K 35/17, A61K 39/00, A61K 47/24, A61K 47/28, A61K 47/34, A61K 47/42, A61K 48/00, A61K 48/0033, A61K 48/0041, A61K 48/005, A61K2039/5156, A61K2039/5158, A61K2039/53, A61K2039/585, B82Y 5/00, C07K 14/7051, C07K 14/70521, C07K 16/28, C07K 16/2803, C07K 16/2809, C07K 16/2818, C07K2317/55, C07K2317/73, C12N 5/0636, C12N 5/10, C12N2502/99, C12N2510/00Filed as Takeda Pharmaceutical Company Limited2025-12-29Shinobu KUWAE | pending |
| PLASMA KALLIKREIN INHIBITORS AND USES THEREOF FOR TREATING PEDIATRIC HEREDITARY ANGIOEDEMA ATTACKC07K 16/40, A61P 7/10, A61K 9/0019, A61K2039/505, A61K2039/54, A61K2039/545, A61K2039/55, C07K2317/565Filed as Takeda Pharmaceutical Company Limited2025-12-22Christina Nurse | pending |
| HTT REPRESSORS AND USES THEREOFA61K 48/005, C07K 14/4702, A61P 25/14, A61P 25/28, A61K 38/00, A61K 38/1709, C07K 14/47, C07K2319/81, C12N 15/86, C12N2750/14143Filed as TAKEDA PHARMACEUTICAL COMPANY LIMITED2025-12-22Simon MOORE | pending |
| CCR8 ANTIBODIES, ANTIBODY CONJUGATES, AND USES THEREOFFiled as TAKEDA PHARMACEUTICAL COMPANY LIMITED2025-12-08ADRIAN SCHWARTZ-MITTLEMAN | pending |
| COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 FAMILY 7 SUBFAMILY A MEMBER 1 (CYP7A1) EXPRESSIONA61K 31/713, C12N 15/1137, A61K 47/549, C12N2310/14, C12N2310/3183, C12N2310/321, C12N2310/343, C12N2320/11, C12N2320/32, C12Y 114/13, C12Y 114/14, C12N2310/315, C12N2310/344, C12N2310/3521, C12N2310/322, C12N2310/3533Filed as Takeda Pharmaceutical Company Limited2025-12-03Bernard Allan | pending |
| T CELL PROGENITOR PRODUCTION METHODA61P 35/00, C12N 5/0636, A61K 40/31, A61K 40/11, A61K 35/17, A61K 35/545, C12N2500/02, C12N2500/25, C12N2501/115, C12N2501/125, C12N2501/15, C12N2501/155, C12N2501/16, C12N2501/165, C12N2501/2303, C12N2501/2306, C12N2501/2307, C12N2501/26, C12N2501/42, C12N2501/60, C12N2501/71, C12N2501/999, C12N2506/45, C12N2510/00, C12N2533/52Filed as Takeda Pharmaceutical Company Limited2025-12-02Shin KANEKO | pending |
| USE OF AN OREXIN 2 RECEPTOR AGONIST FOR IMPROVING RESPIRATORY FUNCTION DURING SLEEPA61K 31/4418, A61K 31/445, A61P 11/00, A61P 25/00, A61K 9/0053, A61K 31/40, A61K 45/00Filed as TAKEDA PHARMACEUTICAL COMPANY LIMITED2025-12-01Haruhide KIMURA | pending |
| VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETOA61P 31/22, A61K 31/4184, A61K 31/7056, A61K 9/0053, A61K2300/00, C07H 1/00, C07H 19/04, C07H 19/052Filed as Takeda Pharmaceutical Company Limited2025-11-21Jeffrey Scott DEPUE | pending |
| VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETOA61P 31/22, A61K 31/4184, A61K 31/7056, A61K 9/0053, A61K2300/00, C07H 1/00, C07H 19/04, C07H 19/052Filed as Takeda Pharmaceutical Company Limited2025-11-21Jeffrey Scott DEPUE | pending |
| DETECTION AND TREATMENT OF AATD-LDG01N 33/6893, C12N 15/113, C12N2310/14, C12Q 1/6883, C12Q2600/156, G01N2333/8125, G01N2800/085, G01N2800/50Filed as Takeda Pharmaceutical Company Limited2025-11-21Virginia C. Clark | pending |
| VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETOA61P 31/22, A61K 31/4184, A61K 31/7056, A61K 9/0053, A61K2300/00, C07H 1/00, C07H 19/04, C07H 19/052Filed as Takeda Pharmaceutical Company Limited2025-11-21Jeffrey Scott DEPUE | pending |
| VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETOA61P 31/22, A61K 31/4184, A61K 31/7056, A61K 9/0053, A61K2300/00, C07H 1/00, C07H 19/04, C07H 19/052Filed as Takeda Pharmaceutical Company Limited2025-11-21Jeffrey Scott DEPUE | pending |
| COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLSA61K 9/5123, A61P 3/00, A61K 9/0019, A61K 9/5192, A61K 31/711, A61K 47/18, A61K 47/22, A61K 47/24, A61K 47/26, A61K 47/28Filed as TAKEDA PHARMACEUTICAL COMPANY LIMITED2025-11-12Mohammad Parvez Alam | pending |
| METHODS OF PURIFYING RECOMBINANT ADAMTS13 AND OTHER PROTEINS AND COMPOSITIONS THEREOFC07K 1/14, C12N 9/6489, A61P 7/02, A61P 9/00, C07K 1/16, C07K 1/18, C07K 1/34, C12M 47/12, C12N 7/06, C12N 11/14, C12Y 304/24087Filed as TAKEDA PHARMACEUTICAL COMPANY LIMITED2025-11-11Meinhard Hasslacher | pending |
| RE-EDITABLE TEMPLATES, CELLS, COMPOSITIONS AND METHODS OF MAKINGC12N 5/0636, C12N 15/11, C12N2310/20, C12N 9/226, C07K 14/705, C07K 14/70539, C07K2319/81, C12N 5/0635, C12N 5/0645, C12N 5/0646, C12N 5/0696, C12N 5/10, C12N 9/22, C12N 9/78, C12N 15/1138, C12N 15/907, C12N2510/00, C12Y 305/04001, C12Y 305/04002Filed as TAKEDA PHARMACEUTICAL COMPANY LIMITED2025-11-03John STEELE | pending |
| VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETOFiled as Takeda Pharmaceutical Company Limited2025-10-29Jeffrey Scott DEPUE | pending |
| METHOD FOR EXPANDING CD56+/CD3- CELLSA61K 35/17, A61K 40/15, A61K 40/4211, A61K 40/31, C07K 14/5443, C07K 14/70503, C07K 14/7155, C07K2319/00, C12N 5/0646, C12N 15/62, C12N2501/233, C12N2506/11, C12N2510/00Filed as TAKEDA PHARMACEUTICAL COMPANY LIMITED2025-10-27Yoshiaki KASSAI | pending |
| METHOD FOR PRODUCING PYRROLIDINE COMPOUNDC07D 207/14, Y02P 20/55Filed as TAKEDA PHARMACEUTICAL COMPANY LIMITED2025-10-22Atsuko NISHIGUCHI | pending |
| PYRAZOLOPYRIMIDINE DERIVATIVES AS INHIBITORS OF NLRP3C07D 473/06, C07D 487/04, A61P 25/28, A61P 29/00, A61K 9/2018, A61K 9/2054, A61K 9/4858, A61K 9/4866, A61K 31/519, C07D 498/04, C07D 519/00Filed as Takeda Pharmaceutical Company Limited2025-10-13Satoshi MIKAMI | pending |
| PLASMA KALLIKREIN BINDING PROTEINSC07K 16/40, A61P 7/10, A61P 1/02, A61P 7/00, A61P 7/02, A61P 9/10, A61P 19/06, A61P 43/00, A61P 9/00, A61P 19/02, A61P 25/04, A61P 13/12, A61P 17/02, A61P 31/04, A61P 1/00, A61P 11/00, A61P 29/00, A61K 49/0004, A61K2039/505, C07K2317/76, C07K2317/92Filed as Takeda Pharmaceutical Company Limited2025-10-07Daniel J. Sexton | pending |
| T CELLS FOR USE IN TREATING RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIAA61K 35/17, A61K2239/48, A61K 40/32, A61K 40/11, A61K 31/136, A61K 31/704, A61K 31/7048, A61K 31/7068, A61K2300/00Filed as TAKEDA PHARMACEUTICAL COMPANY LIMITED2025-10-06Cori ABIKOFF | pending |
| METHODS OF LYOPHILIZING LIPID NANOPARTICLESA61K 9/5138, A61K 9/5192, A61P 1/04, A61K 9/0053, A61K 9/10, A61K 9/19, A61K 9/5123, A61K 31/7105, A61K 31/713, A61K 47/02, A61K 47/32, C08J 3/05, C08J2371/02, C08J2399/00Filed as TAKEDA PHARMACEUTICAL COMPANY LIMITED2025-10-03Kanika Suri | pending |
| MARIBAVIR ISOMERS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USINGA61K 31/7056, A61P 31/22, A61K 45/06, G01N 33/94, G01N2430/00, G01N2800/52, G09B 19/00Filed as Takeda Pharmaceutical Company Limited2025-10-01John D. PEABODY III | pending |
| MARIBAVIR ISOMERS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USINGA61K 31/7056, A61P 31/22, A61K 45/06, G01N 33/94, G01N2430/00, G01N2800/52, G09B 19/00Filed as Takeda Pharmaceutical Company Limited2025-10-01John D. Peabody III | 12661368 |
| USE OF MARIBAVIR IN TREATMENT REGIMENSA61K 31/7056, A61P 31/22, A61K 31/365, A61K 31/4166, A61K 31/436, A61K 31/513, A61K 31/515, A61K 31/55, A61K 31/573, A61K 36/38, A61K 45/06, A61K2300/00Filed as Takeda Pharmaceutical Company Limited2025-09-30Heng SONG | pending |
| PLASMA KALLIKREIN BINDING PROTEINSC07K 16/40, A61P 7/10, A61P 37/00, A61P 1/02, A61P 7/02, A61P 9/10, A61P 19/00, A61P 19/06, A61P 43/00, A61P 9/00, A61P 19/02, A61P 25/04, A61P 13/12, A61P 17/02, A61P 1/00, A61P 11/00, A61P 25/00, A61P 29/00, A61P 1/04, A61P 35/00, A61K2039/505, C07K2317/34, C07K2317/55, C07K2317/56, C07K2317/565, C07K2317/76, C07K2317/92, C07K2317/94, G01N 33/573, G01N2333/96455, G01N2500/04Filed as Takeda Pharmaceutical Company Limited2025-09-15Daniel J. Sexton | pending |
| STABILIZED LIQUID AND LYOPHILIZED ADAMTS13 FORMULATIONSA61K 9/19, A61K 38/4886, A61P 7/02, A61P 9/10, Y02A 50/30, A61K 9/0019, A61K 9/08, A61K 47/02, A61K 47/10, A61K 47/183, A61K 47/22, A61K 47/26, C12Y 304/24087Filed as TAKEDA PHARMACEUTICAL COMPANY LIMITED2025-09-11Peter Matthiessen | pending |
| COMPOSITIONS AND METHODS OF CRYOPRESERVING CELLSA01N 1/125, A01N 1/10, C12N 5/544, A01N 1/126, C12N 5/562, A01N 1/162Filed as Takeda Pharmaceutical Company Limited2025-08-27Lan Cao | pending |
| CNS DELIVERY OF THERAPEUTIC AGENTSA61K 38/47, A61K 9/0019, A61K 9/0085, A61K 9/08, A61K 9/19, A61K 35/76, A61K 35/761, A61K 38/46, A61K 38/465, A61K 47/02, A61K 47/26, C07K 14/65, C12N 9/2402, C12N 9/2437, C12Y 301/06008, C12Y 301/06013, C12Y 302/01045, C12Y 302/01046, C12Y 302/0105, C12Y 310/01001Filed as Takeda Pharmaceutical Company Limited2025-08-15Pericles Calias | pending |
| MONOCLONAL ANTIBODY INHIBITOR OF FACTOR XIIAC07K 16/36, A61P 7/10, A61P 27/02, A61P 7/02, A61P 43/00, A61P 9/00, A61P 11/00, A61K2039/505, C07K2317/21, C07K2317/24, C07K2317/34, C07K2317/55, C07K2317/565, C07K2317/76, C07K2317/90, C07K2317/92, C07K2317/94Filed as Takeda Pharmaceutical Company Limited2025-08-12Shauna Mason | pending |
| HETEROCYCLIC COMPOUND AND USE THEREOFC07D 207/14, C07D 405/06, A61P 3/00, A61P 25/00, A61K 31/40, A61K 31/4025, A61K 31/422, A61K 31/427, A61K 31/4439, A61K 31/506, C07D 401/10, C07D 403/06, C07D 403/10, C07D 403/14, C07D 407/06, C07D 407/08, C07D 413/10, C07D 417/06, C07D 417/10Filed as TAKEDA PHARMACEUTICAL COMPANY LIMITED2025-07-31Yasushi HATTORI | pending |
| METHODS AND MATERIALS FOR ASSESSING RESPONSE TO PLASMABLAST- AND PLASMA CELL-DEPLETING THERAPIESC07K 16/2896, G01N 33/56966, A61P 21/04, A61P 37/02, A61P 37/06, A61P 19/02, A61P 1/00, A61P 25/00, A61P 1/04, A61K2039/505, A61K2039/507, C07K2317/21, C07K2317/732, C07K2317/734, C07K2317/92, G01N2333/91148Filed as Takeda Pharmaceutical Company Limited2025-07-14Glennda Smithson | pending |
| METHOD FOR PRODUCING GAMMA DELTA T CELLSC07K 14/7051, C12N 5/0636, C12N 5/10, A61P 35/00, A61K2239/48, A61K 40/35, A61K 40/42, A61K 40/4211, A61K 40/32, A61K 40/31, A61K 40/11, A61K 48/005, A61K2039/55527, A61K2039/572, C07K 14/5443, C07K 16/2803, C07K2317/622, C07K2319/00, C07K2319/03, C12N2500/25, C12N2500/38, C12N2501/125, C12N2501/145, C12N2501/21, C12N2501/2302, C12N2501/2315, C12N2501/2321, C12N2501/26, C12N2501/48, C12N2501/599, C12N2501/727, C12N2506/45, C12N2510/00Filed as Takeda Pharmaceutical Company Limited2025-07-11Shin Kaneko | pending |
| CORONAVIRUS ANTIBODIES AND THERAPEUTIC USES THEREOFC07K 16/104, A61P 31/14, A61K 31/403, A61K 31/427, A61K 31/7068, A61K2039/505, C07K2317/21, C07K2317/23, C07K2317/24, C07K2317/33, C07K2317/52, C07K2317/55, C07K2317/565, C07K2317/76, C07K2317/92Filed as Takeda Pharmaceutical Company Limited2025-07-11Jerry Thomas | pending |
| METHOD FOR PRODUCING GAMMA DELTA T CELLSC07K 14/7051, C12N 5/0636, C12N 5/10, A61P 35/00, A61K2239/48, A61K 40/35, A61K 40/42, A61K 40/4211, A61K 40/32, A61K 40/31, A61K 40/11, A61K 48/005, A61K2039/55527, A61K2039/572, C07K 14/5443, C07K 16/2803, C07K2317/622, C07K2319/00, C07K2319/03, C12N2500/25, C12N2500/38, C12N2501/125, C12N2501/145, C12N2501/21, C12N2501/2302, C12N2501/2315, C12N2501/2321, C12N2501/26, C12N2501/48, C12N2501/599, C12N2501/727, C12N2506/45, C12N2510/00Filed as Takeda Pharmaceutical Company Limited2025-07-11Shin Kaneko | pending |
| METHOD FOR PRODUCING GAMMA DELTA T CELLSC07K 14/7051, C12N 5/0636, C12N 5/10, A61P 35/00, A61K2239/48, A61K 40/35, A61K 40/42, A61K 40/4211, A61K 40/32, A61K 40/31, A61K 40/11, A61K 48/005, A61K2039/55527, A61K2039/572, C07K 14/5443, C07K 16/2803, C07K2317/622, C07K2319/00, C07K2319/03, C12N2500/25, C12N2500/38, C12N2501/125, C12N2501/145, C12N2501/21, C12N2501/2302, C12N2501/2315, C12N2501/2321, C12N2501/26, C12N2501/48, C12N2501/599, C12N2501/727, C12N2506/45, C12N2510/00Filed as Takeda Pharmaceutical Company Limited2025-07-11Shin Kaneko | pending |
| TREATMENT OF PROSTATE CANCERA61K 31/501, A61K 31/519, A61P 35/00, A61K 9/0053, A61K 31/4166, A61K 31/513, A61K 45/06, A61K2300/00Filed as Takeda Pharmaceutical Company Limited2025-07-09Vijaykumar Reddy RAJASEKHAR | 12629370 |
| SUBCUTANEOUS INFUSION KITFiled as TAKEDA PHARMACEUTICAL COMPANY LIMITED2025-07-09EDWARD TANG | pending |
| PLASMA KALLIKREIN BINDING PROTEINS AND USES THEREOF IN TREATING HEREDITARY ANGIOEDEMAC07K 16/40, A61P 7/10, A61P 9/00, A61K 39/395, A61K2039/505, A61K2039/54, A61K2039/545, C07K2317/565, C07K2317/76, C07K2317/92, C12Y 207/03002, C12Y 304/21034Filed as Takeda Pharmaceutical Company Limited2025-07-08Daniel J. Sexton | pending |
| VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETOA61P 31/22, A61K 31/4184, A61K 31/7056, A61K 9/0053, A61K2300/00, C07H 1/00, C07H 19/04, C07H 19/052Filed as Takeda Pharmaceutical Company Limited2025-07-07Jeffrey Scott DEPUE | 12527771 |
| ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF AUTOIMMUNE DISEASESFiled as Takeda Pharmaceutical Company Limited2025-07-03Deborah T. BERG | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on TAK
Company overviewEverything on TAK in one place, with the price.SEC filingsWhat TAK's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat TAK's own officers and directors buy and sell.Who owns itEvery manager reporting a position in TAK.Funds holding itWhich funds and ETFs hold TAK, and how big a bet.LobbyingWhat TAK spends lobbying Congress, and on what.Who lobbies for itThe lobbyists on TAK's account, and who they worked for.